Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20466161 | 0.86 | KDM4E (0.37) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18611912 | 0.86 | KDM4E (0.37) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL17488428 | 0.86 | KDM4E (0.37) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL17488442 | 0.84 | KDM4E (0.36) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL23945366 | 0.83 | KDM4E (0.35) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL25725620 | 0.80 | HRH3 (0.36) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL18908756 | 0.79 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL22837632 | 0.79 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL22930120 | 0.79 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB | |
| SCHEMBL10914222 | 0.79 | KDM4E (0.44) | KDM4ECYP1A2CYP2D6CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CYP1A2 3570/4885CYP2D6 3599/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CYP1A2 3570/4885CYP2D6 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.